Modified 4′-nucleosides as antiviral agents

• US 8,569,478 B2
• Filed: 09/26/2006
• Issued: 10/29/2013
• Est. Priority Date: 09/26/2005
• Status: Active Grant

• Current Assignee: Gilead Sciences Inc.
• Original Assignee: Gilead Pharmasset LLC (Gilead Sciences Inc.)
• Inventors: Du, Jinfa, Furman, Phillip, Sofia, Michael Joseph
• Primary Examiner(s): Crane, Lawrence E
• Application Number:
  US12/067,995
• Publication Number:
  US 20110021454A1
• Time in Patent Office: 2,590 Days
• Field of Search: None
• US Class Current: 536/26.7
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07H 19/06 Pyrimidine radicals
• CPC Class Codes: C07H 19/16 Purine radicals

Abstract

Compounds, methods and compositions for treating a host infected with human immunodeficiency virus and hepatitis B virus comprising administering an effective amount of a described 4′-C-substituted β-D- and β-L-nucleoside or a pharmaceutically acceptable salt or prodrug thereof, are provided.

Claims

1. A compound which is a β

-D- and β

-L-nucleoside or a pharmaceutically acceptable salt thereof, having a structure defined by formula (I) or by formula (II);

2. The compound of claim 1, wherein the nucleoside is a 4′

-C-substituted-3′

-fluoro-2′

,3′

-dideoxynucleoside.

3. The compound of claim 1, wherein the nucleoside is a 4′

-C-substituted-3′

-azido-2′

,3′

-dideoxynucleoside.

4. The compound of claim 1, wherein the nucleoside is a 4′

-C-ethynyl-3′

-fluoro-2′

,3′

-dideoxynucleoside.

5. The compound of claim 1, wherein the nucleoside is a 4′

-C-ethynyl-3′

-azido-2′

,3′

-dideoxynucleoside.

6. The compound of claim 1, wherein the nucleoside is a 4′

-C-ethynyl-3′

-fluoro-3′

-deoxythymidine.

7. The compound of claim 1, wherein the nucleoside is a 4′

-C-ethynyl-3′

-azido-3′

-deoxythimidine.